Join the Firdapse group to help and get support from people like you.
Firdapse News
Catalyst Pharmaceuticals Receives U.S. FDA Approval for Increased Maximum Daily Dose for Firdapse
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) – Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse Expanding Patient Population to Include Pediatric Patients
Firdapse is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) – Catalyst Pharmaceuticals, Inc. ("Catalyst")...
FDA Medwatch Alert: Jacobus Pharmaceutical Company Inc. Issues Voluntary Worldwide Recall of Ruzurgi (amifampridine) 10 mg Tablets Due to Yeast, Mold, and Bacterial Contamination
September 13, 2021 – Plainsboro, New Jersey, Jacobus Pharmaceutical Company Inc. is voluntarily recalling 3 lots of Ruzurgi® (amifampridine) 10 mg tablets to the consumer level. The products have ...
FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome
November 28, 2018 – The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare...
Ask a question
To post your own question to this support group, sign in or create an account.